Efficacy and safety of lenvatinib in 124 Japanese patients with anaplastic thyroid cancer

被引：2
|
作者：
Takahashi, Shunji [1 ]
Tahara, Makoto [2 ]
Ito, Koichi [3 ]
Tori, Masayuki [4 ]
Sakata, Yukinori [5 ]
Ishii, Mika [6 ]
Yoishida, Akira [6 ]
机构：
[1] Japanese Fdn Canc Res, Inst Canc, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Tokyo, Japan
[3] Ito Hosp, Tokyo, Japan
[4] Osaka Police Hosp, Osaka, Japan
[5] Eisai Col Ltd, Tokyo, Japan
[6] Kanagawa Hlth Serv Assoc, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz338.094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO3 - 3 -
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)
    Higashiyama, Takuya
    Sugino, Kiminori
    Hara, Hisato
    Ito, Ken-Ichi
    Nakashima, Noriaki
    Onoda, Naoyoshi
    Tori, Masayuki
    Katoh, Hiroshi
    Kiyota, Naomi
    Ota, Ichiro
    Suganuma, Nobuyasu
    Hibi, Yatsuka
    Nemoto, Toshimitsu
    Takahashi, Shunji
    Yane, Katsunari
    Ioji, Tetsuya
    Kojima, Shinsuke
    Kaneda, Hideaki
    Sugitani, Iwao
    Tahara, Makoto
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : 210 - 218
  • [2] Lenvatinib for Anaplastic Thyroid Cancer
    Tahara, Makoto
    Kiyota, Naomi
    Yamazaki, Tomoko
    Chayahara, Naoko
    Nakano, Kenji
    Inagaki, Lina
    Toda, Kazuhisa
    Enokida, Tomohiro
    Minami, Hironobu
    Imamura, Yoshinori
    Sasaki, Tatsuya
    Suzuki, Takuya
    Fujino, Katsuki
    Dutcus, Corina E.
    Takahashi, Shunji
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [3] Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
    Huang, Dongmei
    Zhang, Jinming
    Zheng, Xiangqian
    Gao, Ming
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [4] Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction
    Koyama, Satoshi
    Miyake, Naritomo
    Fujiwara, Kazunori
    Morisaki, Tsuyoshi
    Fukuhara, Takahiro
    Kitano, Hiroya
    Takeuchi, Hiromi
    EUROPEAN THYROID JOURNAL, 2018, 7 (03) : 139 - 144
  • [5] Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
    Boudin, Laurys
    Morvan, Jean-Baptiste
    Thariat, Juliette
    Metivier, Denis
    Marcy, Pierre-Yves
    Delarbre, David
    CURRENT ONCOLOGY, 2022, 29 (10) : 7718 - 7731
  • [6] Lung cavitation in patients with anaplastic thyroid cancer treated with lenvatinib
    Murayama, Daisuke
    Yamamoto, Yayoi
    Matsui, Ai
    Yasukawa, Mio
    Okamoto, Saki
    Toda, Soji
    Iwasaki, Hiroyuki
    GLAND SURGERY, 2022, 11 (06) : 963 - 969
  • [7] Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview
    Sparano, Clotilde
    Godbert, Yann
    Attard, Marie
    Do Cao, Christine
    Zerdoud, Slimane
    Roudaut, Nathalie
    Joly, Charlotte
    Berdelou, Amandine
    Hadoux, Julien
    Lamartina, Livia
    Schlumberger, Martin
    Leboulleux, Sophie
    ENDOCRINE-RELATED CANCER, 2021, 28 (01) : 15 - 26
  • [8] Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer
    Iwasaki, Hiroyuki
    Toda, Soji
    Takahashi, Akari
    Masudo, Katsuhiko
    ONCOLOGY LETTERS, 2023, 26 (03)
  • [9] Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer
    Iniguez-Ariza, Nicole M.
    Ryder, Mabel M.
    Hilger, Crystal R.
    Bible, Keith C.
    THYROID, 2017, 27 (07) : 923 - 927
  • [10] Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer
    Mijin Kim
    Jonghwa Ahn
    Dong Eun Song
    Jee Hee Yoon
    Ho-Cheol Kang
    Dong Jun Lim
    Won Gu Kim
    Tae Yong Kim
    Won Bae Kim
    Young Kee Shong
    Min Ji Jeon
    Bo Hyun Kim
    Endocrine, 2021, 71 : 427 - 433
12345